Avenue therapeutics, inc. (ATXI)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities:
Net loss

-

-

-

-

-

-

-

-

-10,377

-6,243

-2,948

-2,406

-661

-

-

-

-

Net loss

-1,242

-

-2,242

-6,982

-11,269

-

-

-

-

-

-

-

-

-

-

-

1,047

Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation

215

254

299

535

751

494

372

321

350

334

246

19

5

5

5

9

9

Change in fair value of convertible notes payable

-

-

-

-

-

-

-

-

-

0

0

95

4

0

0

-89

89

Change in fair value of warrant liabilities

-

-

-

-

-

-

-

-

-

0

0

454

-3

80

19

89

0

Debt discount amortization

-

-

-

-

-

-

-

-

-

0

106

35

33

31

32

31

29

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-48

94

-85

-93

102

-307

-37

186

-78

262

104

22

0

-

-

-

-

Accounts payable and accrued expenses

-311

-800

173

-7,586

5,453

1,764

-2,136

-1,519

3,016

823

1,088

-42

362

110

-164

261

-192

Accounts payable and accrued expenses - related party

119

-2

-29

-41

-401

116

186

18

114

-23

-91

231

220

244

189

190

206

Interest payable

-

-

-

-

-

-

-

-

-

0

-56

51

-52

57

0

0

0

Accrued interest - related party

-

-

-

-

-

-

-

-

-

0

-120

16

58

60

50

42

29

Net cash used in operating activities

-1,171

-4,996

-1,714

-13,981

-5,568

-1,238

-4,136

-6,023

-6,819

-4,268

-1,879

-621

-34

-

-

-

-

Cash flows from investing activities:
Milestone payment for research and development licenses

1,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturity of Short-term investments (certificates of deposits)

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Maturity of Short-term investments (certificates of deposit)

-

-

-

-

-

0

0

0

-10,000

-

-

-

-

-

-

-

-

Net cash used in investing activities

-1,000

-

-

-

-

0

0

0

10,000

0

-10,000

0

0

-

-

-

-

Cash flows from financing activities:
Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

234

-

-

-

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-239

-877

Issuance of common shares

-

0

0

0

35,000

-

-

-

0

-

-

-

-

-

-

-

-

Offering costs

-

0

0

12

2,655

-

-

-

0

-

-

-

-

-

-

-

-

Proceeds from notes payable - related party

-

-

-

-

-

-

-

-

-

-

-

567

71

-

-

-

-

Net cash provided by financing activities

-

0

0

-12

32,345

-

-

-

0

0

-6,754

35,304

-163

-

-

-

-

Net change in cash

-2,171

-

-

-

26,777

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from notes payable - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

259

875

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

259

875

Net change in cash

-

-

-

-

-

-

-

-

3,181

-4,268

-18,633

34,683

-197

167

-2

20

-2

Cash paid for interest

-

-

-

-

-

-

-

-

-

6

172

10

115

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

35

85

Non-cash financing activities:
Unpaid offering costs

-

0

0

821

12

-

-

-

-

-

-

-

-

-

-

-

-

Unpaid deferred financing costs

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-